Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Pillai A, et al. Among authors: mendelowitz a. Schizophr Res. 2018 Mar;193:263-268. doi: 10.1016/j.schres.2017.06.059. Epub 2017 Jul 19. Schizophr Res. 2018. PMID: 28734907
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM; PROACTIVE Study. Buckley PF, et al. Among authors: mendelowitz aj. Schizophr Bull. 2015 Mar;41(2):449-59. doi: 10.1093/schbul/sbu067. Epub 2014 May 27. Schizophr Bull. 2015. PMID: 24870446 Free PMC article. Clinical Trial.
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Buckley PF, et al. Among authors: mendelowitz a. Psychiatr Serv. 2016 Dec 1;67(12):1370-1372. doi: 10.1176/appi.ps.201500466. Epub 2016 Aug 1. Psychiatr Serv. 2016. PMID: 27476806 Clinical Trial.
Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial.
Schoretsanitis G, Mendelowitz A, Malur C, Braga RJ, Schooler NR, John M, de Leon J, Kane JM, Petrides G. Schoretsanitis G, et al. Among authors: mendelowitz a. Schizophr Res. 2020 Apr;218:309-311. doi: 10.1016/j.schres.2020.02.008. Epub 2020 Feb 24. Schizophr Res. 2020. PMID: 32107101 Clinical Trial. No abstract available.
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Robinson DG, et al. Among authors: mendelowitz a. Am J Psychiatry. 2006 Dec;163(12):2096-102. doi: 10.1176/ajp.2006.163.12.2096. Am J Psychiatry. 2006. PMID: 17151160 Clinical Trial.
20 results